Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seniprutug (BCD-180) in Axial Spondyloarthritis
NCT05445076Phase 2Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of seniprutug in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), sponsored by BIOCAD. Started Apr 2022; status: active, not recruiting.
02
Drugs
seniprutug
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05445076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445076.